genomic analysis of calgb 40601 for her2-positive breast cancer
Published 7 years ago • 91 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
2:46
calgb 40601 alliance: impact of dual her2 targeting on pcr
-
4:26
independent validation of the her2dx genomic test in her2-positive breast cancer
-
1:38
genomic assays for chemotherapy decisions in er-positive/her2-negative breast cancer
-
2:39
charles m. perou, phd, discusses genomic signatures and dual her2-targeting in breast cancer
-
2:34
genomic assays impact treatment decisions in patients with er breast cancer
-
1:06
immunotherapy combination in her2-positive breast cancer
-
0:48
dr. hudis discusses the calgb 40601 study in breast cancer
-
2:47
genomic assays impact treatment decisions in patients with er breast cancer
-
1:30
utilizing genomic assays for decision making in early stage breast cancer
-
0:52
dr. graff on genomic risk prediction in hr /her2- breast cancer
-
26:38
genomic assays and breast cancer
-
4:33
the her pathway and cancer
-
6:12
next-generation sequencing in her2 breast cancer
-
2:07
recommendations for her2 testing in metastatic breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
1:37
dr. piccart on genomic testing in breast cancer
-
1:37
dr. meisel on optimizing genomic assays in early-stage hr-positive, her2-negative breast cancer
-
1:29
the genetics of breast cancer complete response
-
1:42
treatment landscape for her2-positive breast cancer